Quality of life with trimetazidine

Research output: Contribution to journalArticlepeer-review


Trimetazidine, a metabolic agent with anti-ischemic properties, has strong evidence of efficacy and tolerability in the treatment of patients with ischemic cardiomyopathy, including subjects with chronic angina and heart failure. There is now a growing evidence that trimetazidine has also a positive impact on quality of life of these patients. This seems to be a consequence of the clinical benefits provided by trimetazidine on one hand, and of its optimal tolerability profile on the other. Benefits of trimetazidine administration include symptom relief, particularly reduction of episodes of angina and dyspnea with a resulting improvement in exercise tolerance. The clinical effectiveness of trimetazidine can alone explain its impact on quality of life in a disease, such as ischemic cardiomyopathy, where poor quality of life is strongly related to the limitation of daily living activities imposed by symptoms.

Original languageEnglish
Pages (from-to)28-31
Number of pages4
JournalHeart and Metabolism
Issue number52
Publication statusPublished - 2011


  • Ischemic cardiomyopathy
  • Quality of life
  • Trimetazidine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Quality of life with trimetazidine'. Together they form a unique fingerprint.

Cite this